GSK Wades Into The Pooled Approach To Tropical Disease Research
Executive Summary
GlaxoSmithKline CEO Andrew Witty's proposal for companies to pool their patents to develop medicines for neglected tropical diseases is a somewhat unusual call for collaboration in the pharmaceutical industry, but not entirely without precedent
You may also be interested in...
Effectiveness Of Priority Review Voucher, Orphan Status Part Of Tropical Disease Hearing
September public hearing will continue FDA's look into rare and neglected disease drug development.
Pre-Competitive Collaboration Would Help Pharmaceutical Productivity Crisis - If Lawyers Could Get Out Of The Way
CAMBRIDGE, Mass. - Greater R&D collaboration was the theme of the day at the star-studded U.S.-India Chamber of Commerce biopharma and healthcare summit
Pre-Competitive Collaboration Would Help Pharmaceutical Productivity Crisis - If Lawyers Could Get Out Of The Way
Pre-commercial collaborations and R&D network expansions fall in the cross hairs of IP lawyers, who look to protect everything they can as intellectual property. But with big pharma desperate to speed up drug development and conserve resources, it's likely the R&D heads have the upper hand, at least for now.